Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation
Abstract Background Atrial fibrillation (AF) is associated with a higher incidence of stroke, heart failure, and mortality. Risk assessment of clinical outcomes in patients hospitalized acutely with AF remains a challenge. Purpose To investigate if soluble urokinase plasminogen activator receptor (s...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Journal of Arrhythmia |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/joa3.70077 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139781309136896 |
|---|---|
| author | Frederik Dencker Wisborg Nora Olsen El Caidi Ida Arentz Taraldsen Sandra Tonning Aginsha Kandiah Mohammed El‐Sheikh Hashmat S. Z. Bahrami Ove Andersen Line Jee Hartmann Rasmussen Jens Hove Ulrik Dixen Johannes Grand |
| author_facet | Frederik Dencker Wisborg Nora Olsen El Caidi Ida Arentz Taraldsen Sandra Tonning Aginsha Kandiah Mohammed El‐Sheikh Hashmat S. Z. Bahrami Ove Andersen Line Jee Hartmann Rasmussen Jens Hove Ulrik Dixen Johannes Grand |
| author_sort | Frederik Dencker Wisborg |
| collection | DOAJ |
| description | Abstract Background Atrial fibrillation (AF) is associated with a higher incidence of stroke, heart failure, and mortality. Risk assessment of clinical outcomes in patients hospitalized acutely with AF remains a challenge. Purpose To investigate if soluble urokinase plasminogen activator receptor (suPAR) levels at admission to the Emergency Department (ED) are associated with 1‐year all‐cause mortality in patients admitted with AF. Methods A prospective cohort study of patients consecutively admitted to the medical ED of a university hospital in Copenhagen, Denmark, between 2020 and 2022 with symptoms of COVID‐19. Patients were included if they were admitted with AF as the primary or secondary diagnosis. All patients had suPAR measured at the index admission, and follow‐up was up to 1 year. The association between suPAR and 1‐year mortality was investigated with multivariate Cox regression. We adjusted for age, sex, smoking, C‐reactive protein, creatinine, hemoglobin, albumin, and comorbidities. Results Of the 7,258 patients included during the period, 362 (5.0%) patients were admitted with AF as the primary or secondary diagnosis. Due to missing data, 23 (6.4%) patients were excluded. Among the remaining 339 patients, 68 (20.1%) patients were dead at follow‐up. The multivariate Cox regression showed that elevated suPAR was independently associated with an increased risk of 1‐year mortality, with a hazard ratio of 1.12 (95% confidence interval: 1.05–1.20, p < 0.001). Conclusion Elevated suPAR levels were significantly associated with 1‐year all‐cause mortality in patients acutely admitted with AF to the ED. |
| format | Article |
| id | doaj-art-ee0fbaebc18049f0b8a69cfd7774e39d |
| institution | OA Journals |
| issn | 1880-4276 1883-2148 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Arrhythmia |
| spelling | doaj-art-ee0fbaebc18049f0b8a69cfd7774e39d2025-08-20T02:30:08ZengWileyJournal of Arrhythmia1880-42761883-21482025-04-01412n/an/a10.1002/joa3.70077Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillationFrederik Dencker Wisborg0Nora Olsen El Caidi1Ida Arentz Taraldsen2Sandra Tonning3Aginsha Kandiah4Mohammed El‐Sheikh5Hashmat S. Z. Bahrami6Ove Andersen7Line Jee Hartmann Rasmussen8Jens Hove9Ulrik Dixen10Johannes Grand11Department of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Clinical Research Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Clinical Research Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkDepartment of Cardiology Copenhagen University Hospital, Amager and Hvidovre Hvidovre DenmarkAbstract Background Atrial fibrillation (AF) is associated with a higher incidence of stroke, heart failure, and mortality. Risk assessment of clinical outcomes in patients hospitalized acutely with AF remains a challenge. Purpose To investigate if soluble urokinase plasminogen activator receptor (suPAR) levels at admission to the Emergency Department (ED) are associated with 1‐year all‐cause mortality in patients admitted with AF. Methods A prospective cohort study of patients consecutively admitted to the medical ED of a university hospital in Copenhagen, Denmark, between 2020 and 2022 with symptoms of COVID‐19. Patients were included if they were admitted with AF as the primary or secondary diagnosis. All patients had suPAR measured at the index admission, and follow‐up was up to 1 year. The association between suPAR and 1‐year mortality was investigated with multivariate Cox regression. We adjusted for age, sex, smoking, C‐reactive protein, creatinine, hemoglobin, albumin, and comorbidities. Results Of the 7,258 patients included during the period, 362 (5.0%) patients were admitted with AF as the primary or secondary diagnosis. Due to missing data, 23 (6.4%) patients were excluded. Among the remaining 339 patients, 68 (20.1%) patients were dead at follow‐up. The multivariate Cox regression showed that elevated suPAR was independently associated with an increased risk of 1‐year mortality, with a hazard ratio of 1.12 (95% confidence interval: 1.05–1.20, p < 0.001). Conclusion Elevated suPAR levels were significantly associated with 1‐year all‐cause mortality in patients acutely admitted with AF to the ED.https://doi.org/10.1002/joa3.70077acute cardiovascular carearrrhythmiaatrial fibrillationmortalitysuPAR |
| spellingShingle | Frederik Dencker Wisborg Nora Olsen El Caidi Ida Arentz Taraldsen Sandra Tonning Aginsha Kandiah Mohammed El‐Sheikh Hashmat S. Z. Bahrami Ove Andersen Line Jee Hartmann Rasmussen Jens Hove Ulrik Dixen Johannes Grand Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation Journal of Arrhythmia acute cardiovascular care arrrhythmia atrial fibrillation mortality suPAR |
| title | Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation |
| title_full | Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation |
| title_fullStr | Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation |
| title_full_unstemmed | Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation |
| title_short | Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic biomarker in acutely admitted patients with atrial fibrillation |
| title_sort | soluble urokinase plasminogen activator receptor supar as a prognostic biomarker in acutely admitted patients with atrial fibrillation |
| topic | acute cardiovascular care arrrhythmia atrial fibrillation mortality suPAR |
| url | https://doi.org/10.1002/joa3.70077 |
| work_keys_str_mv | AT frederikdenckerwisborg solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT noraolsenelcaidi solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT idaarentztaraldsen solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT sandratonning solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT aginshakandiah solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT mohammedelsheikh solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT hashmatszbahrami solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT oveandersen solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT linejeehartmannrasmussen solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT jenshove solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT ulrikdixen solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation AT johannesgrand solubleurokinaseplasminogenactivatorreceptorsuparasaprognosticbiomarkerinacutelyadmittedpatientswithatrialfibrillation |